ClinVar Miner

Submissions for variant NM_020919.4(ALS2):c.4573dup (p.Val1525fs)

dbSNP: rs730882256
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 3
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Cirak Lab, University Hospital Cologne RCV001089474 SCV000998815 likely pathogenic Infantile-onset ascending hereditary spastic paralysis 2019-10-30 criteria provided, single submitter research
Broad Center for Mendelian Genomics, Broad Institute of MIT and Harvard RCV001089474 SCV002507023 pathogenic Infantile-onset ascending hereditary spastic paralysis 2022-05-04 criteria provided, single submitter curation The homozygous p.Val1525GlyfsTer17 variant in ALS2 was identified by our study in 1 individual with infantile-onset ascending hereditary spastic paralysis. The variant has been reported in 3 Turkish individuals with infantile-onset ascending hereditary spastic paralysis (PMID: 24562058, 33155358), segregated with disease in 1 affected relatives from 1 family (PMID: 24562058), and was absent from large population studies. This variant has been reported in ClinVar (Variation ID: 183240) as pathogenic by OMIM and as likely pathogenic by Cirak Lab, University Hospital Cologne. This variant is predicted to cause a frameshift, which alters the protein’s amino acid sequence beginning at position 1525 and leads to a premature termination codon 17 amino acids downstream. This alteration is then predicted to lead to a truncated or absent protein. Loss of function of the ALS2 gene is an established disease mechanism in autosomal recessive infantile-onset ascending hereditary spastic paralysis. The presence of this variant in 3 affected homozygotes and in 3 individuals with infantile-onset ascending hereditary spastic paralysis increases the likelihood that the p.Val1525GlyfsTer17 variant is pathogenic (PMID: 24562058). In summary, this variant meets criteria to be classified as pathogenic for infantile-onset ascending hereditary spastic paralysis in an autosomal recessive manner based on the predicted impact of the variant, its absence from control populations, and multiple homozygous occurrences in affected individuals. ACMG/AMP Criteria applied: PVS1, PM2, PM3, PP1 (Richards 2015).
OMIM RCV000162072 SCV000212105 pathogenic Amyotrophic lateral sclerosis type 2, juvenile 2014-03-25 no assertion criteria provided literature only

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.